TXNIP and diabetes mellitus: (ii) A triple drug combination treatment, comprising of TXNIP-IN1, Mito-Tempo, and ML-SA1 (TMM), targeting TXNIP and mitochondrial–lysosomal stress are effective in normalizing mitophagic flux and transcription factor TFEB and PGC-1α nuclear translocation in rMC1 under a high glucose environment, as seen in diabetes.